Mark Sabag - Teva Pharmaceutical Ex Commercial
| TEV Stock | EUR 21.20 0.70 3.41% |
Insider
Mark Sabag is Ex Commercial of Teva Pharmaceutical Industries
| Age | 52 |
| Phone | 972 3 914 8213 |
| Web | https://www.tevapharm.com |
Mark Sabag Latest Insider Activity
Tracking and analyzing the buying and selling activities of Mark Sabag against Teva Pharmaceutical stock is an integral part of due diligence when investing in Teva Pharmaceutical. Mark Sabag insider activity provides valuable insight into whether Teva Pharmaceutical is net buyers or sellers over its current business cycle. Note, Teva Pharmaceutical insiders must abide by specific rules, including filing SEC forms every time they buy or sell Teva Pharmaceutical'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Mark Sabag over six months ago Disposition of 100000 shares by Mark Sabag of Teva Pharma at 13.5209 subject to Rule 16b-3 |
Teva Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0363 % which means that it generated a profit of $0.0363 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2414) %, meaning that it generated substantial loss on money invested by shareholders. Teva Pharmaceutical's management efficiency ratios could be used to measure how well Teva Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Akira Kato | Shionogi Co | N/A | |
| Iwaaki Taniguchi | Takeda Pharmaceutical | N/A | |
| Thomas Castellano | Catalent | 43 | |
| Aymeric Chatelier | Ipsen SA | 54 | |
| Jeannette Astorga | Zoetis Inc | 48 | |
| Takeshi Shiota | Shionogi Co | N/A | |
| David Loew | Ipsen SA | 56 | |
| MBA MBA | Dr Reddys Laboratories | 54 | |
| Regis Mulot | Ipsen SA | 57 | |
| Susumu Mitsumori | Shionogi Co | N/A | |
| Karen Santiago | Catalent | 52 | |
| Daniel Rankin | Swedish Orphan Biovitrum | 43 | |
| Isao Teshirogi | Shionogi Co | 64 | |
| Constantine Saroukos | Takeda Pharmaceutical | 52 | |
| Haruo Naito | Eisai Co | 76 | |
| Gabriele Ricci | Takeda Pharmaceutical | 45 | |
| Guido Oelkers | Swedish Orphan Biovitrum | 58 | |
| Anders MD | Swedish Orphan Biovitrum | 67 | |
| Andrew Plump | Takeda Pharmaceutical | 58 | |
| Henrik Stenqvist | Swedish Orphan Biovitrum | 55 | |
| Nadeem Sarwar | Eisai Co | N/A | |
Management Performance
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 |
Teva Pharmaceutical Leadership Team
Elected by the shareholders, the Teva Pharmaceutical's board of directors comprises two types of representatives: Teva Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Teva. The board's role is to monitor Teva Pharmaceutical's management team and ensure that shareholders' interests are well served. Teva Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Teva Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eli Shani, Ex Portfolio | ||
| David Stark, Ex Officer | ||
| Mark Sabag, Ex Commercial | ||
| Eric Drape, Ex Operations | ||
| Sven Dethlefs, Ex Commercial | ||
| Kevin Mannix, VP Relations | ||
| Eliyahu Kalif, Ex CFO | ||
| Kathleen Veit, Global VP | ||
| Kare Schultz, CEO Pres | ||
| Amir Weiss, VP Officer |
Teva Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Teva Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 | |||
| Profit Margin | (0.16) % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 28.17 B | |||
| Shares Outstanding | 1.11 B | |||
| Shares Owned By Insiders | 2.00 % | |||
| Shares Owned By Institutions | 49.70 % | |||
| Price To Book | 1.16 X | |||
| Price To Sales | 0.61 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Teva Stock
Teva Pharmaceutical financial ratios help investors to determine whether Teva Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Teva with respect to the benefits of owning Teva Pharmaceutical security.